Danazol administration after gonadotrophin-releasing hormone analogue reduces rebound of uterine myomas
Non-randomised trial
OA: bronze
CC0
⤵ 8 in-corpus citations
AI-generated summary
Danazol administration after GnRHa therapy for uterine myomas reduced rebound of uterine volume by approximately 30% compared to controls, while also improving bone mineral content.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We report the results of administration of danazol after suspension of gonadotrophin-releasing hormone analogue (GnRHa) therapy for uterine myomas. A total of 21 women with uterine myomas was treated with 100 mg danazol for 6 months after GnRHa therapy. Uterine volume and endocrine status were monitored monthly by ultrasound and assay of plasma gonadotrophins, oestradiol and progesterone. The results show a rebound of uterine volume about 30% less than in controls at the end of danazol therapy. Menstrual cyclicity returned after 65 +/- 3 days in 16 subjects and five patients remained amenorrhoeic. Hormone assays confirmed renewed ovarian function in the women whose menstrual periods returned. Bone mineral content was substantially reduced during GnRHa treatment but improved significantly during danazol therapy even in the women who remained amenorrhoeic. These results show the utility of danazol in prolonging the therapeutic effects of GnRHa. The mechanism by which danazol inhibits rebound of uterine volume may be due to its antiprogesterone effects on uterine myomas.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (15)
- Danazol binding and translocation of steroid receptors via openalex
- Danazol binding to rat androgen, glucocorticoid, progesterone, and estrogen receptors: correlation with biologic activity via openalex
- Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women via openalex
- The effect of danazol on anterior pituitary function via openalex
- Treatment of endometriosis with an antigonadotropin, Danazol. A laparoscopic and histologic evaluation via openalex
- doi:10.1016/s0015-0282(16)59464-3 via openalex
- doi:10.1016/0020-7292(90)90194-p via openalex
- doi:10.1210/jcem.76.5.8496313 via openalex
- doi:10.1159/000299821 via openalex
- doi:10.1210/jcem.76.2.8432797 via openalex
- doi:10.3109/00016348309154224 via openalex
- doi:10.1016/0002-9378(83)90463-5 via openalex
- doi:10.1016/s0015-0282(16)59763-5 via openalex
- doi:10.1111/j.1471-0528.1990.tb01804.x via openalex
- W2466802647 via openalex
Cited by (8)
- Androgen Signaling in Uterine Diseases: New Insights and New Targets 2022
- Potential use of aromatase inhibitors in gynecology 2006
- Hemodynamic effect of danazol therapy in women with uterine leiomyomata 2003
- A benefit-risk assessment of medical treatment for uterine leiomyomas 2002
- Short-term treatment of uterine fibromyomas with danazol 1999
- Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis 1999
- Surgical and medical treatment of adenomyosis 1998
- Efficacy of preoperative medical treatment in facilitating hysteroscopic endometrial resection, myomectomy and metroplasty: literature review 1998
Source provenance
- openalex
- last seen: 2026-05-14T06:08:44.784461+00:00
- pubmed
- last seen: 2026-10-08T22:00:10.289599+00:00
License: CC0
· commercial use OK